These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 31889219)

  • 1. Inositide-Dependent Nuclear Signalling in Health and Disease.
    Follo MY; Ratti S; Manzoli L; Ramazzotti G; Faenza I; Fiume R; Mongiorgi S; Suh PG; McCubrey JA; Cocco L
    Handb Exp Pharmacol; 2020; 259():291-308. PubMed ID: 31889219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nuclear inositides: inconsistent consistencies.
    Divecha N; Clarke JH; Roefs M; Halstead JR; D'Santos C
    Cell Mol Life Sci; 2000 Mar; 57(3):379-93. PubMed ID: 10823239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nuclear Inositides and Inositide-Dependent Signaling Pathways in Myelodysplastic Syndromes.
    Xian J; Owusu Obeng E; Ratti S; Rusciano I; Marvi MV; Fazio A; De Stefano A; Mongiorgi S; Cappellini A; Ramazzotti G; Manzoli L; Cocco L; Follo MY
    Cells; 2020 Mar; 9(3):. PubMed ID: 32178280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nuclear inositide specific phospholipase C signalling - interactions and activity.
    Faenza I; Fiume R; Piazzi M; Colantoni A; Cocco L
    FEBS J; 2013 Dec; 280(24):6311-21. PubMed ID: 23890371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inositide-dependent signaling pathways as new therapeutic targets in myelodysplastic syndromes.
    Mongiorgi S; Finelli C; Yang YR; Clissa C; McCubrey JA; Billi AM; Manzoli L; Suh PG; Cocco L; Follo MY
    Expert Opin Ther Targets; 2016 Jun; 20(6):677-87. PubMed ID: 26610046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nuclear phosphoinositides: location, regulation and function.
    Fiume R; Keune WJ; Faenza I; Bultsma Y; Ramazzotti G; Jones DR; Martelli AM; Somner L; Follo MY; Divecha N; Cocco L
    Subcell Biochem; 2012; 59():335-61. PubMed ID: 22374096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nuclear PI-PLCβ1: an appraisal on targets and pathology.
    Follo MY; Faenza I; Piazzi M; Blalock WL; Manzoli L; McCubrey JA; Cocco L
    Adv Biol Regul; 2014 Jan; 54():2-11. PubMed ID: 24296032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topology of inositol lipid signal transduction in the nucleus.
    Maraldi NM; Zini N; Santi S; Manzoli FA
    J Cell Physiol; 1999 Nov; 181(2):203-17. PubMed ID: 10497300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nuclear inositide signalling -- expansion, structures and clarification.
    Irvine RF
    Biochim Biophys Acta; 2006; 1761(5-6):505-8. PubMed ID: 16574480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nuclear inositide signaling and cell cycle.
    Ratti S; Ramazzotti G; Faenza I; Fiume R; Mongiorgi S; Billi AM; McCubrey JA; Suh PG; Manzoli L; Cocco L; Follo MY
    Adv Biol Regul; 2018 Jan; 67():1-6. PubMed ID: 29102395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New frontiers of inositide-specific phospholipase C in nuclear signalling.
    Cocco L; Maraldi NM; Manzoli FA
    Eur J Histochem; 2004; 48(1):83-8. PubMed ID: 15145779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nuclear inositide signaling: an appraisal of phospholipase C beta 1 behavior in myelodysplastic and leukemia cells.
    Cocco L; Follo MY; Faenza I; Bavelloni A; Billi AM; Martelli AM; Manzoli L
    Adv Enzyme Regul; 2007; 47():2-9. PubMed ID: 17335878
    [No Abstract]   [Full Text] [Related]  

  • 13. Nuclear inositide signaling in myelodysplastic syndromes.
    Follo MY; Mongiorgi S; Finelli C; Clissa C; Ramazzotti G; Fiume R; Faenza I; Manzoli L; Martelli AM; Cocco L
    J Cell Biochem; 2010 Apr; 109(6):1065-71. PubMed ID: 20058233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nuclear inositides.
    D'Santos C; Clarke JH; Roefs M; Halstead JR; Divecha N
    Eur J Histochem; 2000; 44(1):51-60. PubMed ID: 10868293
    [No Abstract]   [Full Text] [Related]  

  • 15. Inositide signaling: Nuclear targets and involvement in myelodysplastic syndromes.
    Cocco L; Faenza I; Follo MY; Ramazzotti G; Gaboardi GC; Billi AM; Martelli AM; Manzoli L
    Adv Enzyme Regul; 2008; 48():2-9. PubMed ID: 18280812
    [No Abstract]   [Full Text] [Related]  

  • 16. Nuclear inositides: facts and perspectives.
    Martelli AM; Manzoli L; Cocco L
    Pharmacol Ther; 2004 Jan; 101(1):47-64. PubMed ID: 14729392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inositide-specific phospholipase C signalling in the nucleus.
    Cocco L; Rhee SG; Gilmour RS; Manzoli FA
    Eur J Histochem; 2000; 44(1):45-50. PubMed ID: 10868292
    [No Abstract]   [Full Text] [Related]  

  • 18. Nuclear PI-PLCβ1 and myelodysplastic syndromes: genetics and epigenetics.
    Follo MY; Mongiorgi S; Finelli C; Piazzi M; Faenza I; Ramazzotti G; Santi P; McCubrey JA; Martelli AM; Cocco L
    Curr Pharm Des; 2012; 18(13):1751-4. PubMed ID: 22352752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The physiology and pathology of inositide signaling in the nucleus.
    Ramazzotti G; Faenza I; Fiume R; Matteucci A; Piazzi M; Follo MY; Cocco L
    J Cell Physiol; 2011 Jan; 226(1):14-20. PubMed ID: 20658523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nuclear phosphoinositides and their impact on nuclear functions.
    Shah ZH; Jones DR; Sommer L; Foulger R; Bultsma Y; D'Santos C; Divecha N
    FEBS J; 2013 Dec; 280(24):6295-310. PubMed ID: 24112514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.